All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 Study Intervention and comparison (in HF clinic unless stated otherwise) Population Outcomes Comments SIGNAL-HF trial: NP monitoring (in primary care): Treatment increased to achieve target (NT-proBNP reduction of 50% from baseline), 9 months Clinical monitoring (in primary care): Therapy increased at clinician s discretion according to clinical assessment, 9 months Age mean: 78(7) NYHA class II-IV, LVEF < 50%, stable in primary care Elevated NPs (NT- proBNP levels males > 800, females > 1000 ng/L) Troughton IPD: Mortality Recruited from primary TIME-CHF trial: (Pfisterer , Brunner-la , Sanders-van , Sanders-van , Kaufmann ) NP monitoring: Therapy intensified to reach BNP target n=251 with rEF, 59 with pEF Clinically monitoring: Therapy intensified to reach target (NYHA II), 18 months n=248 with rEF, 64 with pEF Age 60 years, NYHA class II with current therapy, HF admission in the last year, elevated NPs (NT- proBNP of 400pg/mL if < pg/mL if 75y) Stratified by LVEF status Troughton IPD: Mortality* Recruited from multiple centres in Switzerlan d and Germany ACEi/ARB: Angiotensin converting enzyme inhibitor and/or Aldosterone receptor blocker, BB: Beta-blocker, IV: Intravenous therapy, NP: natriuretic peptides including BNP and NT-proBNP Monitoring Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 